Anti-Factor D Antibodies for Sustained Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective systemic inhibition of the alternative pathway (AP) of the complement system to treat AP-dependent pathologies, as previous methods have shown that blocking Factor D activity is not feasible due to its fast turnover, and there is a lack of suitable animal models for testing anti-human Factor D monoclonal antibodies.
Innovation Solution
Development of anti-human Factor D monoclonal antibodies that specifically bind to Factor D, inhibiting the AP pathway without affecting the classical or lectin pathways, and the creation of genetically modified mice expressing human Factor D to serve as animal models for testing these antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If factor D activity is blocked systemically, then AP complement activation is inhibited, but the fast turnover of factor D makes sustained inhibition difficult to achieve
Solution Approach 1:
The patent uses anti-factor D monoclonal antibodies as intermediary molecules that bind to factor D and prevent its interaction with C3bBb, thereby mediating sustained inhibition of AP complement activation despite the fast turnover of factor D. The antibodies act as a bridge that continuously neutralizes factor D as it is regenerated in the system.
2Reliability
If anti-factor D monoclonal antibodies are developed for systemic inhibition, then therapeutic potential increases, but the lack of appropriate animal models prevents effective testing and validation
Solution Approach 1:
The patent fundamentally changes the biological parameter of factor D species specificity by using genetically modified mice that express human factor D instead of mouse factor D. This parameter change enables the use of standard murine models for testing human-specific anti-factor D antibodies, thereby resolving the adaptability issue.
3Quantity of substance
If factor D concentration in blood is low (approximately 2 μg/ml), then therapeutic inhibition might be easily achieved, but the fast turnover rate complicates sustained blocking
Solution Approach 1:
The patent ensures continuous therapeutic action by administering anti-factor D monoclonal antibodies that continuously bind and neutralize factor D molecules as they are rapidly turned over in the bloodstream. The antibodies remain active in the system, providing ongoing inhibition that matches the fast regeneration rate of factor D.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit AP-mediated diseases by reducing C3bBb generation, demonstrating potential therapeutic benefits in conditions such as macular degeneration, arthritis, and hemolytic uremic syndrome, with sustained inhibition achievable through appropriate dosing and administration.
Implementation Method 1
anti-factor D monoclonal antibodies that specifically bind to Factor D
Data Source
AI summary
This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-factor D antibody. Specifically, the invention relates to methods of treating an AP-mediated disease or AP-mediated disorder in an individual by contacting the individual with an anti-factor D antibody.